Successful memory response following a booster dose with a virosome-formulated hepatitis A vaccine delayed up to 11 years

Clinical and Vaccine Immunology

Volumn 18, Issue 5, 2011, Pages 885-887

  Hatz, Christoph ^a,b   Van Der Ploeg, Robert ^a   Beck, Bernhard R ^a   Frösner, Gert ^c   Hunt, Marjory ^d   Herzog, Christian ^d  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; VIROSOME VACCINE;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG RESPONSE; FEMALE; HEPATITIS A; HUMAN; IMMUNIZATION; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SEX DIFFERENCE; SINGLE DRUG DOSE;

ADULT; AGED; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; TIME FACTORS; VACCINES, VIROSOME;

EID: 79955744066     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00358-10     Document Type: Article

References (13)

1. Askling, H. H., L. Rombo, Y. Andersson, S. Martin, and K. Ekdahl. 2009. Hepatitis A risk in travelers. J. Travel Med. 16:233-238.
2. Beck, B. R., C. Hatz, R. Bronnimann, and C. Herzog. 2003. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. Clin. Infect. Dis. 37:e126-e128.
3. Bovier, P. A. 2008. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines 7:1141-1150.
4. Bovier, P. A., et al. 2010. Predicted 30-year protection after vaccination with an inactivated virosome hepatitis A vaccine. J. Med. Virol. 82:1629-1634.
5. Cederna, J. B., D. Klinzman, and J. T. Stapleton. 1999. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 18:892-898.
6. Centers for Disease Control and Prevention. 2006. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55:1-23.
7. D'Acremont, V., C. Herzog, and B. Genton. 2006. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J. Travel Med. 13:78-83.
8. Iwarson, S., M. Lindh, and L. Widerstrom. 2004. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J. Travel Med. 11:120-121. (Pubitemid 38523688)
9. Landry, P., S. Tremblay, R. Darioli, and B. Genton. 2000. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 19:399-402.
10. Nalin, D. R., et al. 1993. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J. Hepatol. 18(Suppl. 2):S51-S55. (Pubitemid 24035905)
11. Reuman, P. D., P. Kubilis, W. Hurni, L. Brown, and D. Nalin. 1997. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15:1157-1161. (Pubitemid 27357202)
12. World Health Organization. 2000. Hepatitis A vaccines - WHO position paper. Wkly. Epidemiol. Rec. 75:38-44.
13. Zachoval, R., M. Kroener, M. Brommer, and F. Deinhardt. 1990. Serology and interferon production during the early phase of acute hepatitis A. J. Infect. Dis. 161:353-354.